Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXRJI2)

• Drug Name: Pyrrolo[2,3-d]pyrimidine derivative 28 Drug Info
• Synonyms: PMID28705083-Compound-26
• Cross-matching ID:
  PubChem CID: 118025736
  TTD Drug ID: DMXRJI2

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[2]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[3]
Zanubrutinib	DMJWRQP	Mantle cell lymphoma	2A85.5	Approved	[4]
Pirtobrutinib	DMRG1X3	Non-hodgkin lymphoma	2B33.5	Approved	[5]
GDC-0853	DMBEL3Q	Multiple sclerosis	8A40	Phase 3	[6]
ICP-022	DMU72KL	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[7]
Tolebrutinib	DML19V6	Multiple sclerosis	8A40	Phase 3	[8]
CC-292	DMJR9H0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[9]
BMS-986142	DMZB8AJ	Rheumatoid arthritis	FA20	Phase 2	[6]
LOU064	DME8O5K	Chronic idiopathic urticaria	EB00.1	Phase 2	[10]

Drug(s) Targeting PI3-kinase delta (PIK3CD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[3]
Idelalisib	DM602WT	Chronic lymphocytic leukaemia	2A82.0	Approved	[11]
Umbralisib	DMYRBO1	Follicular lymphoma	2A80	Approved	[12]
IPI-145	DMWA24P	Follicular lymphoma	2A80	Approved	[13]
Leniolisib	DMWAD93	Stomach cancer	2B72	Approved	[14]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[15]
INCB50465	DMZJP2T	Diffuse large B-cell lymphoma	2A81	Phase 2	[16]
ME-401	DMK0UOY	Follicular lymphoma	2A80	Phase 2	[16]
RP6530	DMYILGK	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[16]
Parsaclisib	DMYBIFS	Follicular lymphoma	2A80	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase delta (PIK3CD)	TTGBPJE	PK3CD_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[1]

References

• [1] Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
• [3] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [8] Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
• [9] Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [13] PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
• [14] Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
• [15] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.